APA (7th ed.) Citation

DJ, B., SA, B., AJ, K., RM, F., C, S., & J, B. (2008). Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A Phase I, open-label, dose-escalation clinical study. Clinical therapeutics, 30(10), 1806. https://doi.org/10.1016/j.clinthera.2008.10.017

Chicago Style (17th ed.) Citation

DJ, Burge, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, and Bannink J. "Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-directed Small Modular Immunopharmaceutical Protein Therapeutic, in Patients with Rheumatoid Arthritis: A Phase I, Open-label, Dose-escalation Clinical Study." Clinical Therapeutics 30, no. 10 (2008): 1806. https://doi.org/10.1016/j.clinthera.2008.10.017.

MLA (9th ed.) Citation

DJ, Burge, et al. "Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-directed Small Modular Immunopharmaceutical Protein Therapeutic, in Patients with Rheumatoid Arthritis: A Phase I, Open-label, Dose-escalation Clinical Study." Clinical Therapeutics, vol. 30, no. 10, 2008, p. 1806, https://doi.org/10.1016/j.clinthera.2008.10.017.